Haemostatix is developing a new class of coagulant for the control of surgical bleeding. The company's lead product, PeproStat, has recently completed a clinical trial in liver surgery patients. PeproStat is based on a peptide conjugated to recombinant albumin, and is formulated as a sterile solution that is applied topically to an internal wound. We are now gearing up to progress the product into Phase IIb and beyond. We have a highly innovative platform technology and an exciting pipeline. Our second product, HXP12 ReadyFlow is a purely synthetic peptide formulated in a gel, and is at a pre-clinical stage.
We are looking for an experienced, innovative individual who will manage and optimise the out-sourced supply chain for PeproStat. They will also lead process development and supply chain implementation for the pipeline products, and contribute to formulation development (depending on their experience). A minimum of 15 years in the pharmaceutical / biopharmaceutical industry is required as is a thorough understanding of regulatory/quality standards. The candidate will have a wide knowledge of the global contract manufacturing industry and have experience of contract negotiation and management.